36 results on '"Rabe, Ingrid B."'
Search Results
2. West Nile Virus and Other Nationally Notifiable Arboviral Diseases — United States, 2017
- Author
-
Curren, Emily J., Lehman, Jennifer, Kolsin, Jonathan, Walker, William L., Martin, Stacey W., Staples, J. Erin, Hills, Susan L., Gould, Carolyn V., Rabe, Ingrid B., Fischer, Marc, and Lindsey, Nicole P.
- Published
- 2018
3. Donor-Derived West Nile Virus Infection in Solid Organ Transplant Recipients
- Author
-
Winston, Drew J, Vikram, Holenarasipur R, Rabe, Ingrid B, Dhillon, Gundeep, Mulligan, David, Hong, Johnny C, Busuttil, Ronald W, Nowicki, Marek J, Mone, Thomas, Civen, Rachel, Tecle, Selam A, Trivedi, Kavita K, and Hocevar, Susan N
- Subjects
Infectious Diseases ,Orphan Drug ,Biodefense ,Vaccine Related ,Rare Diseases ,Clinical Research ,Vector-Borne Diseases ,Emerging Infectious Diseases ,Neurosciences ,Genetics ,Prevention ,West Nile Virus ,Transplantation ,Organ Transplantation ,Infection ,Good Health and Well Being ,Antibodies ,Viral ,Humans ,Immunoglobulin M ,Immunosuppressive Agents ,Kidney Transplantation ,Liver Transplantation ,Lung Transplantation ,Lymph Nodes ,Male ,Middle Aged ,RNA ,Viral ,Spleen ,Tissue Donors ,West Nile Fever ,West Nile virus ,Donor-derived infection ,West Nile Virus Transplant-Associated Transmission Investigation Team ,Medical and Health Sciences ,Surgery - Abstract
We describe four solid-organ transplant recipients with donor-derived West Nile virus (WNV) infection (encephalitis 3, asymptomatic 1) from a common donor residing in a region of increased WNV activity. All four transplant recipients had molecular evidence of WNV infection in their serum and/or cerebrospinal fluid (CSF) by reverse transcription polymerase chain reaction (RT-PCR) testing. Serum from the organ donor was positive for WNV IgM but negative for WNV RNA, whereas his lymph node and spleen tissues tested positive for WNV by RT-PCR. Combination therapy included intravenous immunoglobulin (4 cases), interferon (3 cases), fresh frozen plasma with WNV IgG (2 cases), and ribavirin (1 case). Two of the four transplant recipients survived.Review of the 20 published cases of organ-derived WNV infection found that this infection is associated with a high incidence of neuroinvasive disease (70%) and severe morbidity and mortality (30%). Median time to onset of symptomatic WNV infection was 13 days after transplantation (range 5-37 days). Initial unexplained fever unresponsive to antibiotic therapy followed by rapid onset of neurologic deficits was the most common clinical presentation. Confirmation of infection was made by testing serum and CSF for both WNV RNA by RT-PCR and WNV IgM by serological assays. Treatment usually included supportive care, reduction of immunosuppression, and frequent intravenous immunoglobulin. The often negative results for WNV by current RT-PCR and serological assays and the absence of clinical signs of acute infection in donors contribute to the sporadic occurrence of donor-derived WNV infection. Potential organ donors should be assessed for unexplained fever and neurological symptoms, particularly if they reside in areas of increased WNV activity.
- Published
- 2014
4. Update : Noncongenital Zika Virus Disease Cases — 50 U.S. States and the District of Columbia, 2016
- Author
-
Hall, Victoria, Walker, William L., Lindsey, Nicole P., Lehman, Jennifer A., Kolsin, Jonathan, Landry, Kimberly, Rabe, Ingrid B., Hills, Susan L., Fischer, Marc, Staples, J. Erin, Gould, Carolyn V., and Martin, Stacey W.
- Published
- 2018
5. Fatal Transplant-Associated West Nile Virus Encephalitis and Public Health Investigation—California, 2010
- Author
-
Rabe, Ingrid B, Schwartz, Brian S, Farnon, Eileen C, Josephson, S Andrew, Webber, Allison B, Roberts, John Paul, de Mattos, Angelo M, Gallay, Brian J, van Slyck, Sean, Messenger, Sharon L, Yen, Cynthia J, Bloch, Evan M, Drew, Clifton P, Fischer, Marc, and Glaser, Carol A
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Clinical Sciences ,Kidney Disease ,Rare Diseases ,Clinical Research ,Transplantation ,Prevention ,Vaccine Related ,Biodefense ,Emerging Infectious Diseases ,Infectious Diseases ,West Nile Virus ,Vector-Borne Diseases ,Organ Transplantation ,2.2 Factors relating to the physical environment ,Aetiology ,Renal and urogenital ,Infection ,Good Health and Well Being ,Aged ,Female ,Humans ,Kidney Transplantation ,Male ,Middle Aged ,Public Health ,Tissue Donors ,West Nile Fever ,West Nile virus ,Transplant-associated transmission ,Encephalitis ,WNV Transplant Investigation Team ,Medical and Health Sciences ,Surgery ,Clinical sciences ,Immunology - Abstract
BackgroundIn December 2010, a case of West Nile virus (WNV) encephalitis occurring in a kidney recipient shortly after organ transplantation was identified.MethodsA public health investigation was initiated to determine the likely route of transmission, detect potential WNV infections among recipients from the same organ donor, and remove any potentially infected blood products or tissues. Available serum, cerebrospinal fluid, and urine samples from the organ donor and recipients were tested for WNV infection by nucleic acid testing and serology.ResultsTwo additional recipients from the same organ donor were identified, their clinical and exposure histories were reviewed, and samples were obtained. WNV RNA was retrospectively detected in the organ donor's serum. After transplantation, the left kidney recipient had serologic and molecular evidence of WNV infection and the right kidney recipient had prolonged but clinically inapparent WNV viremia. The liver recipient showed no clinical signs of infection but had flavivirus IgG antibodies; however, insufficient samples were available to determine the timing of infection. No remaining infectious products or tissues were identified.ConclusionsClinicians should suspect WNV as a cause of encephalitis in organ transplant recipients and report cases to public health departments for prompt investigation of the source of infection. Increased use of molecular testing and retaining pretransplantation sera may improve the ability to detect and diagnose transplant-associated WNV infection in organ transplant recipients.
- Published
- 2013
6. List of Contributors
- Author
-
Acosta, Anna M., primary, Acuin, Jose M., additional, Adam, Rodney D., additional, Afroze, Farzana, additional, Ahmed, Nadia, additional, Ahmed, Sabeena, additional, Ahmed, Tahmeed, additional, Ahmed, A.M. Shamsir, additional, Ali, S. Asad, additional, Ali, Ibne K., additional, Alroy, Karen A., additional, Ananthakrishnan, Ashwin N., additional, Ansong, Daniel, additional, Anstead, Gregory M., additional, Appleby, Laura J., additional, Armah, George E., additional, Aronson, Naomi E., additional, Aston, Stephen J., additional, Barnett, Elizabeth D., additional, Bartelt, Luther A., additional, Bates, Imelda, additional, Bausch, Daniel G., additional, Beadling, Charles W., additional, Beeching, Nicholas J., additional, Bennish, Michael L., additional, Bern, Caryn, additional, Bernstein, Wendy B., additional, Bird, Brian H., additional, Bloom, Allyson K., additional, Bodeker, Gerard, additional, Boyer Chammard, Timothée, additional, Bradsher, Robert W., additional, Brooker, Simon J., additional, Brooks, W. Abdullah, additional, Brouqui, Philippe, additional, Brown, Michael, additional, Brown, Michael R., additional, Broyles, Laura N., additional, Bruschi, Fabrizio, additional, Bundy, Donald A.P., additional, Burton, Matthew, additional, Cabrera-Sosa, Luis, additional, Callahan, Michael V., additional, Carapetis, Jonathan R., additional, Cardemil, Cristina V., additional, Carrol, Enitan D., additional, Caswell, Rachel, additional, Caumes, Eric, additional, Cavalheiro, Ana P., additional, Chan, Abner L., additional, Charunwatthana, Prakaykaew, additional, Checkley, Anna M., additional, Chen, Lin H., additional, Chher, Tepirou, additional, Chiong, Charlotte M., additional, Chisti, M. Jobayer, additional, Christiani, David C., additional, Clark, Taryn N., additional, Connor, Bradley A., additional, Conway, Devin J., additional, Cooper, Philip J., additional, Cope, Jennifer R., additional, Coughlin, R. Richard, additional, Coulibaly, Yaya I., additional, Coyle, Christina M., additional, Crozier, Ian, additional, Cunliffe, Nigel A., additional, Cupido, Blanche, additional, Curren, Emily J., additional, Danta, Mark, additional, Day, Nicholas P.J., additional, Debboun, Mustapha, additional, DeFraites, Robert F., additional, Dekumyoy, Paron, additional, del Castillo, Maria, additional, den Hoed, Caroline M., additional, de Silva, Nilanthi, additional, Deye, Gregory, additional, Dillingham, Rebecca A., additional, Drancourt, Michel, additional, Durward, Callum S., additional, Eddleston, Michael, additional, El-Kamary, Samer S., additional, Elshaboury, Ramy H., additional, Endtz, Hubert P., additional, Endy, Timothy P., additional, Fang, Shona C., additional, Fawzi, Wafaie, additional, Feasey, Nicholas A., additional, Field, Vanessa K., additional, Fischer, Marc, additional, Forsyth, Kevin, additional, Fournier, Pierre-Edouard, additional, Friedlander, Arthur M., additional, Furin, Jennifer J., additional, Gandhi, Ronak G., additional, Garcia, Hector H., additional, Garcia, Lynne S., additional, Geretti, Anna Maria, additional, Gikas, Achilleas, additional, Gilman, Robert H., additional, Giri, Sidhartha, additional, Gkika, Meropi, additional, Gordon, Melita A., additional, Gosselin, Richard A., additional, Gotuzzo, Eduardo, additional, Gould, Carolyn V., additional, Graeff-Teixeira, Carlos, additional, Graham, Stephen M., additional, Grant, Alison D., additional, Graybill, John R., additional, Graz, Bertrand, additional, Green, Stephen T., additional, Griffiths, Jeffrey K., additional, Griffiths, Michael J., additional, Gryseels, Bruno, additional, Gubler, Duane J., additional, Guhadasan, Rathi, additional, Hall, Aron J., additional, Hamer, Davidson H., additional, Hand, Robert M., additional, Harley, David, additional, Harris, Jason B., additional, Hassall, Oliver, additional, Hay, Roderick J., additional, Hickey, Patrick, additional, Hill, David R., additional, Hills, Susan L., additional, Hobdell, Martin H., additional, Hochberg, Natasha S., additional, Hopkins, Donald R., additional, Hossain, M. Iqbal, additional, Hotez, Peter J., additional, Howard, Cynthia R., additional, Hu, Victor, additional, Hung, Chien-Ching, additional, Islam, Munirul, additional, Iturriza-Gómara, Miren, additional, Joekes, Elizabeth, additional, Johnston, Victoria, additional, Jose, Jo-Ann, additional, Junghanss, Thomas, additional, Kamgno, Joseph, additional, Kampondeni, Sam, additional, Kang, Gagandeep, additional, Kazanjian, Powel, additional, Keshtkar-Jahromi, Maryam, additional, Keshtkar-Jahromi, Marzieh, additional, Keystone, Jay S., additional, Kim, Arthur Y., additional, Kim, Sung-Han, additional, King, Christopher L., additional, Kittitrakul, Chatporn, additional, Kleine, Christian, additional, Klion, Amy D., additional, Knight, Richard, additional, Koren, Michael, additional, Kottilil, Shyamasundaran, additional, Krause, Peter J., additional, Krishna, Sanjeev, additional, Kuhn, Jens H., additional, Kuipers, Ernst J., additional, LaBeaud, Angelle D., additional, Labra, Patrick John P., additional, Lalloo, David G., additional, Lambert, Saba, additional, Lanternier, Fanny, additional, LaRocque, Regina C., additional, Last, Anna, additional, Lawrenson, John, additional, Le, Thuy, additional, Lee, Keun Hwa, additional, Lewis, David A., additional, Libraty, Daniel H., additional, Lo, Nathan C., additional, Lockwood, Diana N.J., additional, Lockwood, Stephen J., additional, Lommerse, Kinke, additional, López-Vélez, Rogelio, additional, Lortholary, Olivier, additional, Mabey, David, additional, Magill, Alan J., additional, Maguiña, Ciro P., additional, Manji, Hadi, additional, Marks, Michael, additional, Maurin, Max, additional, Mayaud, Philippe, additional, Mayosi, Bongani M., additional, M'baya, Bridon, additional, McCarthy, Matthew W., additional, McCartney, Daniel, additional, McCormick, Joseph B., additional, McKew, Stephen, additional, McLellan, Susan L.F., additional, McMinn, Peter C., additional, Mertz, Gregory, additional, Milner, Danny A., additional, Molyneux, Elizabeth M., additional, Montgomery, Susan P., additional, Moonah, Shannon, additional, Moss, William J., additional, Murrell, K. Darwin, additional, Nanda, Neha, additional, Navarro, Eileen E., additional, Ndayizeye, Leonard, additional, Neafie, Ronald C., additional, Negroni, Ricardo, additional, Nelson, Ann M., additional, Newton, Paul N., additional, Nichol, Stuart T., additional, Norman, Francesca F., additional, Nunes, Marcio R.T., additional, Nutman, Thomas B., additional, Nyirenda, Tonney S., additional, Ochoa, Theresa J., additional, O'Farrell, Nigel, additional, Olayemi, Edeghonghon, additional, Oldfield, Edward C., additional, Omidian, Zahra, additional, Ordaya, Eloy E., additional, Paddock, Christopher D., additional, Paessler, Slobodan, additional, Papanikolaou, Ilias C., additional, Paris, Luc, additional, Parry, Christopher M., additional, Patel, Pragna, additional, Peacock, Sharon J., additional, Peeling, Rosanna W., additional, Persson, Hans, additional, Phillips, Jonathan J., additional, Phillips, Richard O., additional, Poovorawan, Kittiyod, additional, Powers, Ann M., additional, Qamar, Farah Naz, additional, Qureshi, Sonia, additional, Rabe, Ingrid B., additional, Rahman, Atif, additional, Rahmati, Elham, additional, Raizes, Elliot, additional, Ramalho-Ortigao, Marcelo, additional, Raoult, Didier, additional, Rein, Michael F., additional, Retik, Alan B., additional, Reynes, Jean-Marc, additional, Rhatigan, Joseph J., additional, Rickard, Jennifer, additional, Riddle, Mark S., additional, Rimoin, Anne W., additional, Riviello, Robert, additional, Robert, Leon L., additional, Rodrigues, Ema G., additional, Rodriguez, Rubens, additional, Ronald, Allan R., additional, Rosenthal, Benjamin M., additional, Rosmarin, David, additional, Ryan, Edward T., additional, Saavedra, Arturo, additional, Schiaffino, Francesca, additional, Schumacher, Sandra K., additional, Sejvar, James J., additional, Sethi, Aisha, additional, Seung, Kwonjune J., additional, Seydel, Karl B., additional, Shah, Melisa M., additional, Shakoor, Sadia, additional, Shankar, Anuraj H., additional, Sharp, Trueman W., additional, Shin, Sonya S., additional, Shirley, Debbie-Ann, additional, Silachamroon, Udomsak, additional, Smith, Catherine C., additional, Snelling, Thomas L., additional, Solomon, Tom, additional, Staat, Mary Allen, additional, Staples, J. Erin, additional, Steiger, Samantha N., additional, Stewart, Robert C., additional, Stich, August, additional, Strickman, Daniel, additional, Suh, Kathryn N., additional, Suhrbier, Andreas, additional, Sutcliffe, Catherine G., additional, Tappe, Dennis, additional, Taylor, Terrie E., additional, Thanh, Nguyen Tat, additional, Thanh, Nguyen Thi, additional, Thwaites, C. Louise, additional, Thwaites, Guy E., additional, Tiwari, Tejpratap S.P., additional, Tsenempi, Xenia A., additional, Turner, Angus W., additional, van den Broek, Nynke R., additional, van Doorn, H. Rogier, additional, Van Sickels, Nicholas J., additional, Vannier, Edouard, additional, Varda, Briony K., additional, Vasconcelos, Pedro F.C., additional, Vega-López, Francisco, additional, Vietri, Nicholas J., additional, Vinetz, Joseph M., additional, Visvesvara, Govinda S., additional, Vyas, Keyur S., additional, Walsh, Thomas J., additional, Wansbrough-Jones, Mark H., additional, Warraich, Haider J., additional, Warrell, David A., additional, Warrell, Mary J., additional, Watt, George, additional, Wattanagoon, Yupaporn, additional, Watthanakulpanich, Dorn, additional, Weaver, Scott C., additional, Weil, Ana A., additional, Weiss, Louis M., additional, White, Nicholas J., additional, Whitty, Christopher J.M., additional, Wilson, Mary E., additional, Xavier, Ramnik J., additional, Xiao, Lihua, additional, Yoon, In-Kyu, additional, Yu, Hongjie, additional, and Zaidi, Anita K.M., additional
- Published
- 2020
- Full Text
- View/download PDF
7. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012–2016
- Author
-
Walker, William L., Hills, Susan L., Miller, Elaine R., Fischer, Marc, and Rabe, Ingrid B.
- Published
- 2018
- Full Text
- View/download PDF
8. Update : Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus Exposure — United States (Including U.S. Territories), July 2017
- Author
-
Oduyebo, Titilope, Polen, Kara D., Walke, Henry T., Reagan-Steiner, Sarah, Lathrop, Eva, Rabe, Ingrid B., Kuhnert-Tallman, Wendi L., Martin, Stacey W., Walker, Allison T., Gregory, Christopher J., Ades, Edwin W., Carroll, Darin S., Rivera, Maria, Perez-Padilla, Janice, Gould, Carolyn, Nemhauser, Jeffrey B., Beard, C. Ben, Harcourt, Jennifer L., Viens, Laura, Johansson, Michael, Ellington, Sascha R., Petersen, Emily, Smith, Laura A., Reichard, Jessica, Munoz-Jordan, Jorge, Beach, Michael J., Rose, Dale A., Barzilay, Ezra, Noonan-Smith, Michelle, Jamieson, Denise J., Zaki, Sherif R., Petersen, Lyle R., Honein, Margaret A., and Meaney-Delman, Dana
- Published
- 2017
9. A systematic review of the data, methods and environmental covariates used to mapAedes-borne arbovirus transmission risk
- Author
-
Lim, Ah-Young, primary, Jafari, Yalda, additional, Caldwell, Jamie M., additional, Clapham, Hannah E., additional, Gaythorpe, Katy A. M., additional, Hussain-Alkhateeb, Laith, additional, Johansson, Michael A., additional, Kraemer, Moritz U. G., additional, Maude, Richard J., additional, McCormack, Clare P., additional, Messina, Jane P., additional, Mordecai, Erin A., additional, Rabe, Ingrid B., additional, Reiner, Robert C., additional, Ryan, Sadie J., additional, Salje, Henrik, additional, Semenza, Jan C., additional, Rojas, Diana P., additional, and Brady, Oliver J., additional
- Published
- 2023
- Full Text
- View/download PDF
10. Standardized evaluation of Zika nucleic acid tests used in clinical settings and blood screening
- Author
-
Stone, Mars, primary, Bakkour, Sonia, additional, Grebe, Eduard, additional, Emperador, Devy M., additional, Escadafal, Camille, additional, Deng, Xutao, additional, Dave, Honey, additional, Kelly-Cirino, Cassandra, additional, Lackritz, Eve, additional, Rojas, Diana P., additional, Simmons, Graham, additional, Rabe, Ingrid B., additional, and Busch, Michael P., additional
- Published
- 2023
- Full Text
- View/download PDF
11. Update : Interim Guidance for Preconception Counseling and Prevention of Sexual Transmission of Zika Virus for Persons with Possible Zika Virus Exposure — United States, September 2016
- Author
-
Petersen, Emily E., Meaney-Delman, Dana, Neblett-Fanfair, Robyn, Havers, Fiona, Oduyebo, Titilope, Hills, Susan L., Rabe, Ingrid B., Lambert, Amy, Abercrombie, Julia, Martin, Stacey W., Gould, Carolyn V., Oussayef, Nadia, Polen, Kara N.D., Kuehnert, Matthew J., Pillai, Satish K., Petersen, Lyle R., Honein, Margaret A., Jamieson, Denise J., and Brooks, John T.
- Published
- 2016
12. Zika Virus Disease Cases — 50 States and the District of Columbia, January 1–July 31, 2016
- Author
-
Walker, William L., Lindsey, Nicole P., Lehman, Jennifer A., Krow-Lucal, Elisabeth R., Rabe, Ingrid B., Hills, Susan L., Martin, Stacey W., Fischer, Marc, and Staples, J. Erin
- Published
- 2016
13. Interim Guidance for Interpretation of Zika Virus Antibody Test Results
- Author
-
Rabe, Ingrid B., Staples, J. Erin, Villanueva, Julie, Hummel, Kimberly B., Johnson, Jeffrey A., Rose, Laura, Hills, Susan, Wasley, Annemarie, Fischer, Marc, and Powers, Ann M.
- Published
- 2016
14. Zika Virus Infection Among U.S. Pregnant Travelers — August 2015–February 2016
- Author
-
Meaney-Delman, Dana, Hills, Susan L., Williams, Charnetta, Galang, Romeo R., Iyengar, Preetha, Hennenfent, Andrew K., Rabe, Ingrid B., Panella, Amanda, Oduyebo, Titilope, Honein, Margaret A., Zaki, Sherif, Lindsey, Nicole, Lehman, Jennifer A., Kwit, Natalie, Bertolli, Jeanne, Ellington, Sascha, Igbinosa, Irogue, Minta, Anna A., Petersen, Emily E., Mead, Paul, Rasmussen, Sonja A., and Jamieson, Denise J.
- Published
- 2016
15. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009–2012
- Author
-
Rabe, Ingrid B., Miller, Elaine R., Fischer, Marc, and Hills, Susan L.
- Published
- 2015
- Full Text
- View/download PDF
16. St. Louis encephalitis virus possibly transmitted through blood transfusion—Arizona, 2015
- Author
-
Venkat, Heather, Adams, Laura, Sunenshine, Rebecca, Krow‐Lucal, Elisabeth, Levy, Craig, Kafenbaum, Tammy, Sylvester, Tammy, Smith, Kirk, Townsend, John, Dosmann, Melissa, Kamel, Hany, Patron, Roberto, Kuehnert, Matthew, Annambhotla, Pallavi, Basavaraju, Sridhar V., and Rabe, Ingrid B.
- Published
- 2017
- Full Text
- View/download PDF
17. West Nile virus RNA in tissues from donor associated with transmission to organ transplant recipients
- Author
-
Blau, Dianna M., Rabe, Ingrid B., Bhatnagar, Julu, Civen, Rachel, Trivedi, Kavita K., Rollin, Dominique, Hocevar, Susan N., Kuehnert, Matthew, Staples, J. Erin, Zaki, Sherif R., and Fischer, Marc
- Subjects
United States. Centers for Disease Control and Prevention ,West Nile fever -- Health aspects ,Transplantation of organs, tissues, etc. -- Health aspects ,RNA -- Health aspects ,Organ transplant recipients -- Health aspects ,Health - Abstract
We identified West Nile virus (WNV) RNA in skin, fat, muscle, tendon, and bone marrow from a deceased donor associated with WNV transmission through solid organ transplantation. WNV could not [...]
- Published
- 2013
- Full Text
- View/download PDF
18. Investigation of Heartland Virus Disease Throughout the United States, 2013–2017
- Author
-
Staples, J Erin, primary, Pastula, Daniel M, primary, Panella, Amanda J, primary, Rabe, Ingrid B, primary, Kosoy, Olga I, primary, Walker, William L, primary, Velez, Jason O, primary, Lambert, Amy J, primary, and Fischer, Marc, primary
- Published
- 2020
- Full Text
- View/download PDF
19. Expanded Molecular Testing on Patients with Suspected West Nile Virus Disease
- Author
-
Lindsey, Nicole P., primary, Messenger, Sharon L., additional, Hacker, Jill K., additional, Salas, Maria L., additional, Scott-Waldron, Christine, additional, Haydel, Danielle, additional, Rider, Errin, additional, Simonson, Sean, additional, Brown, Catherine M., additional, Patel, Pinal, additional, Smole, Sandra C., additional, Neitzel, David F., additional, Schiffman, Elizabeth K., additional, Palm, Jennifer, additional, Strain, Anna K., additional, Vetter, Sara M., additional, Nefzger, Brian, additional, Fischer, Marc, additional, and Rabe, Ingrid B., additional
- Published
- 2019
- Full Text
- View/download PDF
20. Transmission of Eastern Equine Encephalitis Virus from an Organ Donor to Three Transplant Recipients
- Author
-
Pouch, Stephanie M., Katugaha, Shalika B., Shieh, Wun-Ju, Annambhotla, Pallavi, Walker, William L., Basavaraju, Sridhar V., Jones, Jefferson, Huynh, Thanhthao, Reagan-Steiner, Sarah, Bhatnagar, Julu, Grimm, Kacie, Stramer, Susan L., Gabel, Julie, Lyon, G. Marshall, Mehta, Aneesh K., Kandiah, Prem, Neujahr, David C., Javidfar, Jeffrey, Subramanian, Ram M., Parekh, Samir M., Shah, Palak, Cooper, Lauren, Psotka, Mitchell A., Radcliffe, Rachel, Williams, Carl, Zaki, Sherif R., Staples, J. Erin, Fischer, Marc, Panella, Amanda J., Lanciotti, Robert S., Laven, Janeen J., Kosoy, Olga, Rabe, Ingrid B., and Gould, Carolyn V.
- Subjects
Adult ,Encephalomyelitis, Equine ,Transplantation ,Middle Aged ,Article ,Medical Records ,Tissue Donors ,Transplant Recipients ,Liver Transplantation ,Culicidae ,Fatal Outcome ,Animals ,Encephalitis Virus, Eastern Equine ,Heart Transplantation ,Humans ,Female ,Lung Transplantation - Abstract
BACKGROUND: In fall 2017, three solid organ transplant recipients from a common donor developed encephalitis within one week of transplantation, prompting suspicion of transplant-transmitted infection. Eastern equine encephalitis virus (EEEV) infection was identified during testing of endomyocardial tissue from the heart recipient. METHODS: We reviewed medical records of the organ donor and transplant recipients and tested serum, whole blood, cerebrospinal fluid, and tissue from the donor and recipients for evidence of EEEV infection by multiple assays. We investigated blood transfusion as a possible source of organ donor infection by testing remaining components and serum specimens from blood donors. We reviewed data from the pre-transplant organ donor evaluation and local EEEV surveillance. RESULTS: We found laboratory evidence of recent EEEV infection in all organ recipients and the common donor. Serum collected from the organ donor upon hospital admission tested negative, but subsequent samples obtained prior to organ recovery were positive for EEEV RNA. There was no evidence of EEEV infection among donors of the eight blood products transfused into the organ donor or in products derived from these donations. Veterinary and mosquito surveillance showed recent EEEV activity in counties nearby the organ donor’s county of residence. Neuroinvasive EEEV infection directly contributed to the death of one organ recipient and likely contributed to death in another. CONCLUSIONS: Our investigation demonstrated EEEV transmission through solid organ transplantation. Mosquito-borne transmission of EEEV to the organ donor was the likely source of infection. Clinicians should be aware of EEEV as a cause of transplant-associated encephalitis.
- Published
- 2019
21. Ability To Serologically Confirm Recent Zika Virus Infection in Areas with Varying Past Incidence of Dengue Virus Infection in the United States and U.S. Territories in 2016
- Author
-
Lindsey, Nicole P., primary, Staples, J. Erin, additional, Powell, Krista, additional, Rabe, Ingrid B., additional, Fischer, Marc, additional, Powers, Ann M., additional, Kosoy, Olga I., additional, Mossel, Eric C., additional, Munoz-Jordan, Jorge L., additional, Beltran, Manuela, additional, Hancock, W. Thane, additional, Toews, Karrie-Ann E., additional, Ellis, Esther M., additional, Ellis, Brett R., additional, Panella, Amanda J., additional, Basile, Alison J., additional, Calvert, Amanda E., additional, Laven, Janeen, additional, Goodman, Christin H., additional, Gould, Carolyn V., additional, Martin, Stacey W., additional, Thomas, Jennifer D., additional, Villanueva, Julie, additional, Mataia, Mary L., additional, Sciulli, Rebecca, additional, Gose, Remedios, additional, Whelen, A. Christian, additional, and Hills, Susan L., additional
- Published
- 2018
- Full Text
- View/download PDF
22. Fatal West Nile Virus Infection After Probable Transfusion-Associated Transmission — Colorado, 2012
- Author
-
Kelly, Sharon, Le, Tuan N., Brown, Jennifer A., Lawaczek, Elisabeth W., Kuehnert, Matthew, Rabe, Ingrid B., Staples, J. Erin, and Fischer, Marc
- Subjects
Male ,Immunocompromised Host ,Colorado ,Fatal Outcome ,Lymphoma, Non-Hodgkin ,Humans ,RNA, Viral ,Transfusion Reaction ,Articles ,Antibodies, Viral ,West Nile virus ,West Nile Fever - Published
- 2013
23. Donor-derived West Nile virus infection in solid organ transplant recipients: report of four additional cases and review of clinical, diagnostic, and therapeutic features
- Author
-
Winston, Drew J, Vikram, Holenarasipur R, Rabe, Ingrid B, Dhillon, Gundeep, Mulligan, David, Hong, Johnny C, Busuttil, Ronald W, Nowicki, Marek J, Mone, Thomas, Civen, Rachel, Tecle, Selam A, Trivedi, Kavita K, Hocevar, Susan N, and West Nile Virus Transplant-Associated Transmission Investigation Team
- Subjects
Male ,Medical and Health Sciences ,Antibodies ,Vaccine Related ,Rare Diseases ,Clinical Research ,Biodefense ,Genetics ,Humans ,West Nile Virus ,Viral ,Transplantation ,West Nile Virus Transplant-Associated Transmission Investigation Team ,Prevention ,Neurosciences ,Organ Transplantation ,Middle Aged ,Kidney Transplantation ,Tissue Donors ,Liver Transplantation ,Vector-Borne Diseases ,Infectious Diseases ,Orphan Drug ,Emerging Infectious Diseases ,Good Health and Well Being ,Immunoglobulin M ,RNA ,Surgery ,Lymph Nodes ,Infection ,Donor-derived infection ,Spleen ,West Nile Fever ,Immunosuppressive Agents ,Lung Transplantation - Abstract
We describe four solid-organ transplant recipients with donor-derived West Nile virus (WNV) infection (encephalitis 3, asymptomatic 1) from a common donor residing in a region of increased WNV activity. All four transplant recipients had molecular evidence of WNV infection in their serum and/or cerebrospinal fluid (CSF) by reverse transcription polymerase chain reaction (RT-PCR) testing. Serum from the organ donor was positive for WNV IgM but negative for WNV RNA, whereas his lymph node and spleen tissues tested positive for WNV by RT-PCR. Combination therapy included intravenous immunoglobulin (4 cases), interferon (3 cases), fresh frozen plasma with WNV IgG (2 cases), and ribavirin (1 case). Two of the four transplant recipients survived.Review of the 20 published cases of organ-derived WNV infection found that this infection is associated with a high incidence of neuroinvasive disease (70%) and severe morbidity and mortality (30%). Median time to onset of symptomatic WNV infection was 13 days after transplantation (range 5-37 days). Initial unexplained fever unresponsive to antibiotic therapy followed by rapid onset of neurologic deficits was the most common clinical presentation. Confirmation of infection was made by testing serum and CSF for both WNV RNA by RT-PCR and WNV IgM by serological assays. Treatment usually included supportive care, reduction of immunosuppression, and frequent intravenous immunoglobulin. The often negative results for WNV by current RT-PCR and serological assays and the absence of clinical signs of acute infection in donors contribute to the sporadic occurrence of donor-derived WNV infection. Potential organ donors should be assessed for unexplained fever and neurological symptoms, particularly if they reside in areas of increased WNV activity.
- Published
- 2014
24. Adverse event reports following yellow fever vaccination, 2007–13
- Author
-
Lindsey, Nicole P., primary, Rabe, Ingrid B., additional, Miller, Elaine R., additional, Fischer, Marc, additional, and Staples, J. Erin, additional
- Published
- 2016
- Full Text
- View/download PDF
25. Zika Virus: Common Questions and Answers.
- Author
-
IGBINOSA, IROGUE I., RABE, INGRID B., ODUYEBO, TITILOPE, and RASMUSSEN, SONJA A.
- Subjects
ZIKA virus infections ,SYMPTOMS ,MATERNAL health ,ZIKA virus ,THERAPEUTICS ,VIRAL transmission - Abstract
Since local mosquito-borne transmission of Zika virus was first reported in Brazil in early 2015, the virus has spread rapidly, with active transmission reported in at least 61 countries and territories worldwide, including the United States. Zika virus infection during pregnancy is a cause of microcephaly and other severe brain anomalies. The virus is transmitted primarily through the bite of an infected Aedes mosquito, but other routes of transmission include sexual, mother-to-fetus during pregnancy, mother-to-infant at delivery, laboratory exposure, and, possibly, transfusion of blood products. Most persons with Zika virus infection are asymptomatic or have only mild symptoms; hospitalizations and deaths are rare. When symptoms are present, maculopapular rash, fever, arthralgia, and conjunctivitis are most common. Zika virus testing is recommended for persons with possible exposure (those who have traveled to or live in an area with active transmission, or persons who had sex without a condom with a person with possible exposure) if they have symptoms consistent with Zika virus disease. Testing is also recommended for pregnant women with possible exposure, regardless of whether symptoms are present. Treatment is supportive, and no vaccine is currently available. The primary methods of prevention include avoiding bites of infected Aedes mosquitoes and reducing the risk of sexual transmission. Pregnant women should not travel to areas with active Zika virus transmission, and men and women who are planning to conceive in the near future should consider avoiding nonessential travel to these areas. Condoms can reduce the risk of sexual transmission. [ABSTRACT FROM AUTHOR]
- Published
- 2017
26. Ability To Serologically Confirm Recent Zika Virus Infection in Areas with Varying Past Incidence of Dengue Virus Infection in the United States and U.S. Territories in 2016
- Author
-
Lindsey, Nicole P., Staples, J. Erin, Powell, Krista, Rabe, Ingrid B., Fischer, Marc, Powers, Ann M., Kosoy, Olga I., Mossel, Eric C., Munoz-Jordan, Jorge L., Beltran, Manuela, Hancock, W. Thane, Toews, Karrie-Ann E., Ellis, Esther M., Ellis, Brett R., Panella, Amanda J., Basile, Alison J., Calvert, Amanda E., Laven, Janeen, Goodman, Christin H., Gould, Carolyn V., Martin, Stacey W., Thomas, Jennifer D., Villanueva, Julie, Mataia, Mary L., Sciulli, Rebecca, Gose, Remedios, Whelen, A. Christian, and Hills, Susan L.
- Abstract
ABSTRACTCross-reactivity within flavivirus antibody assays, produced by shared epitopes in the envelope proteins, can complicate the serological diagnosis of Zika virus (ZIKAV) infection. We assessed the utility of the plaque reduction neutralization test (PRNT) to confirm recent ZIKAV infections and rule out misleading positive immunoglobulin M (IgM) results in areas with various levels of past dengue virus (DENV) infection incidence. We reviewed PRNT results of sera collected for diagnosis of ZIKAV infection from 1 January through 31 August 2016 with positive ZIKAV IgM results, and ZIKAV and DENV PRNTs were performed. PRNT result interpretations included ZIKAV, unspecified flavivirus, DENV infection, or negative. For this analysis, ZIKAV IgM was considered false positive for samples interpreted as a DENV infection or negative. In U.S. states, 208 (27%) of 759 IgM-positive results were confirmed to be ZIKAV compared to 11 (21%) of 52 in the U.S. Virgin Islands (USVI), 15 (15%) of 103 in American Samoa, and 13 (11%) of 123 in Puerto Rico. In American Samoa and Puerto Rico, more than 80% of IgM-positive results were unspecified flavivirus infections. The false-positivity rate was 27% in U.S. states, 18% in the USVI, 2% in American Samoa, and 6% in Puerto Rico. In U.S. states, the PRNT provided a virus-specific diagnosis or ruled out infection in the majority of IgM-positive samples. Almost a third of ZIKAV IgM-positive results were not confirmed; therefore, providers and patients must understand that IgM results are preliminary. In territories with historically higher rates of DENV transmission, the PRNT usually could not differentiate between ZIKAV and DENV infections.
- Published
- 2017
- Full Text
- View/download PDF
27. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012–2016.
- Author
-
Hills, Susan L., Fischer, Marc, Rabe, Ingrid B., Walker, William L., and Miller, Elaine R.
- Subjects
- *
JAPANESE B encephalitis vaccines , *CELL culture , *ALLERGIES , *PUBLIC health surveillance - Abstract
Background In March 2009, the U.S. Food and Drug Administration licensed an inactivated Vero cell culture-derived Japanese encephalitis vaccine (JE-VC [IXIARO®]) for use in persons aged ≥17 years. In 2013, licensure was extended to include children aged ≥2 months. A previous analysis reviewed adverse events reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) from May 2009 through April 2012. Methods We reviewed adverse events reported to VAERS following JE-VC administered from May 1, 2012 through April 30, 2016. Adverse event reporting rates were calculated using 802,229 doses distributed. Results During the 4-year period, 119 adverse event reports were received for a reporting rate of 14.8 per 100,000 doses distributed. Nine (8%) adverse events were classified as serious for a reporting rate of 1.1 per 100,000 distributed. The most commonly reported event was hypersensitivity ( n = 24; 20%) for a rate of 3.0 per 100,000 doses distributed; 1 anaphylaxis event was reported. Ten (8%) neurologic events were reported for a rate of 1.2 per 100,000 doses distributed; 2 events were classified as seizures. Sixty-three (53%) adverse events occurred after a first dose of JE-VC. Eighty (67%) adverse events occurred after administration of JE-VC with other vaccines. Eleven (9%) adverse events were reported in children; 1 was considered serious. Conclusions These data continue to support the generally favorable safety profile of JE-VC. Reporting rates of adverse events were similar to those of the previous analysis. Although reporting rates of adverse events in children could not be calculated, there were low numbers of reported events in this age group. Post-licensure adverse event surveillance for this relatively new vaccine continues to be important to monitor adverse event reporting rates and identify possible rare serious events. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
28. Expanded Molecular Testing on Patients with Suspected West Nile Virus Disease.
- Author
-
Lindsey NP, Messenger SL, Hacker JK, Salas ML, Scott-Waldron C, Haydel D, Rider E, Simonson S, Brown CM, Patel P, Smole SC, Neitzel DF, Schiffman EK, Palm J, Strain AK, Vetter SM, Nefzger B, Fischer M, and Rabe IB
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral blood, Child, Child, Preschool, Female, Humans, Immunoglobulin M blood, Male, Middle Aged, Reverse Transcriptase Polymerase Chain Reaction, Young Adult, West Nile Fever diagnosis
- Abstract
Most diagnostic testing for West Nile virus (WNV) disease is accomplished using serologic testing, which is subject to cross-reactivity, may require cumbersome confirmatory testing, and may fail to detect infection in specimens collected early in the course of illness. The objective of this project was to determine whether a combination of molecular and serologic testing would increase detection of WNV disease cases in acute serum samples. A total of 380 serum specimens collected ≤7 days after onset of symptoms and submitted to four state public health laboratories for WNV diagnostic testing in 2014 and 2015 were tested. WNV immunoglobulin M (IgM) antibody and RT-PCR tests were performed on specimens collected ≤3 days after symptom onset. WNV IgM antibody testing was performed on specimens collected 4-7 days after onset and RT-PCR was performed on IgM-positive specimens. A patient was considered to have laboratory evidence of WNV infection if they had detectable WNV IgM antibodies or WNV RNA in the submitted serum specimen. Of specimens collected ≤3 days after symptom onset, 19/158 (12%) had laboratory evidence of WNV infection, including 16 positive for only WNV IgM antibodies, 1 positive for only WNV RNA, and 2 positive for both. Of specimens collected 4-7 days after onset, 21/222 (9%) were positive for WNV IgM antibodies; none had detectable WNV RNA. These findings suggest that routinely performing WNV RT-PCR on acute serum specimens submitted for WNV diagnostic testing is unlikely to identify a substantial number of additional cases beyond IgM antibody testing alone.
- Published
- 2019
- Full Text
- View/download PDF
29. Transmission of Eastern Equine Encephalitis Virus From an Organ Donor to 3 Transplant Recipients.
- Author
-
Pouch SM, Katugaha SB, Shieh WJ, Annambhotla P, Walker WL, Basavaraju SV, Jones J, Huynh T, Reagan-Steiner S, Bhatnagar J, Grimm K, Stramer SL, Gabel J, Lyon GM, Mehta AK, Kandiah P, Neujahr DC, Javidfar J, Subramanian RM, Parekh SM, Shah P, Cooper L, Psotka MA, Radcliffe R, Williams C, Zaki SR, Staples JE, Fischer M, Panella AJ, Lanciotti RS, Laven JJ, Kosoy O, Rabe IB, and Gould CV
- Subjects
- Adult, Animals, Culicidae virology, Encephalitis Virus, Eastern Equine, Encephalomyelitis, Equine blood, Fatal Outcome, Female, Heart Transplantation adverse effects, Humans, Liver Transplantation adverse effects, Lung Transplantation adverse effects, Medical Records, Middle Aged, Encephalomyelitis, Equine transmission, Tissue Donors, Transplant Recipients statistics & numerical data, Transplantation adverse effects
- Abstract
Background: In fall 2017, 3 solid organ transplant (SOT) recipients from a common donor developed encephalitis within 1 week of transplantation, prompting suspicion of transplant-transmitted infection. Eastern equine encephalitis virus (EEEV) infection was identified during testing of endomyocardial tissue from the heart recipient., Methods: We reviewed medical records of the organ donor and transplant recipients and tested serum, whole blood, cerebrospinal fluid, and tissue from the donor and recipients for evidence of EEEV infection by multiple assays. We investigated blood transfusion as a possible source of organ donor infection by testing remaining components and serum specimens from blood donors. We reviewed data from the pretransplant organ donor evaluation and local EEEV surveillance., Results: We found laboratory evidence of recent EEEV infection in all organ recipients and the common donor. Serum collected from the organ donor upon hospital admission tested negative, but subsequent samples obtained prior to organ recovery were positive for EEEV RNA. There was no evidence of EEEV infection among donors of the 8 blood products transfused into the organ donor or in products derived from these donations. Veterinary and mosquito surveillance showed recent EEEV activity in counties nearby the organ donor's county of residence. Neuroinvasive EEEV infection directly contributed to the death of 1 organ recipient and likely contributed to death in another., Conclusions: Our investigation demonstrated EEEV transmission through SOT. Mosquito-borne transmission of EEEV to the organ donor was the likely source of infection. Clinicians should be aware of EEEV as a cause of transplant-associated encephalitis., (© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
30. West Nile Virus and Other Nationally Notifiable Arboviral Diseases - United States, 2017.
- Author
-
Curren EJ, Lehman J, Kolsin J, Walker WL, Martin SW, Staples JE, Hills SL, Gould CV, Rabe IB, Fischer M, and Lindsey NP
- Subjects
- Adolescent, Adult, Aged, Child, Child, Preschool, Disease Notification, Female, Humans, Incidence, Male, Middle Aged, United States epidemiology, Young Adult, Arbovirus Infections epidemiology, Disease Outbreaks, Population Surveillance, West Nile Fever epidemiology
- Abstract
Arthropodborne viruses (arboviruses) are transmitted to humans primarily through the bites of infected mosquitoes or ticks. West Nile virus (WNV) is the leading cause of domestically acquired arboviral disease in the continental United States (1). Other arboviruses, including Jamestown Canyon, La Crosse, Powassan, St. Louis encephalitis, and eastern equine encephalitis viruses, cause sporadic cases of disease and occasional outbreaks. This report summarizes surveillance data reported to CDC from U.S. states in 2017 for nationally notifiable arboviruses. It excludes dengue, chikungunya, and Zika viruses because, in the continental United States, these viruses are acquired primarily through travel. In 2017, 48 states and the District of Columbia (DC) reported 2,291 cases of domestic arboviral disease, including 2,097 (92%) WNV disease cases. Among the WNV disease cases, 1,425 (68%) were classified as neuroinvasive disease (e.g., meningitis, encephalitis, or acute flaccid paralysis), for a national rate of 0.44 cases per 100,000 population. More Jamestown Canyon and Powassan virus disease cases were reported in 2017 than in any previous year. Because arboviral diseases continue to cause serious illness, maintaining surveillance is important to direct and promote prevention activities., Competing Interests: All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
- Published
- 2018
- Full Text
- View/download PDF
31. Update: Noncongenital Zika Virus Disease Cases - 50 U.S. States and the District of Columbia, 2016.
- Author
-
Hall V, Walker WL, Lindsey NP, Lehman JA, Kolsin J, Landry K, Rabe IB, Hills SL, Fischer M, Staples JE, Gould CV, and Martin SW
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, District of Columbia epidemiology, Female, Humans, Infant, Male, Middle Aged, Pregnancy, United States epidemiology, Young Adult, Zika Virus Infection epidemiology
- Abstract
Zika virus is a flavivirus primarily transmitted to humans by Aedes aegypti mosquitoes (1). Zika virus infections also have been documented through intrauterine transmission resulting in congenital infection; intrapartum transmission from a viremic mother to her newborn; sexual transmission; blood transfusion; and laboratory exposure (1-3). Most Zika virus infections are asymptomatic or result in mild clinical illness, characterized by acute onset of fever, maculopapular rash, arthralgia, or nonpurulent conjunctivitis; Guillain-Barré syndrome, meningoencephalitis, and severe thrombocytopenia rarely have been associated with Zika virus infection (1). However, congenital Zika virus infection can result in fetal loss, microcephaly, and other birth defects (1,2). In 2016, a total of 5,168 noncongenital Zika virus disease cases were reported from U.S. states and the District of Columbia. Most cases (4,897, 95%) were in travelers returning from Zika virus-affected areas. A total of 224 (4%) cases were acquired through presumed local mosquitoborne transmission, and 47 (1%) were acquired by other routes. It is important that providers in the United States continue to test symptomatic patients who live in or recently traveled to areas with ongoing Zika virus transmission or had unprotected sex with someone who lives in or traveled to those areas. All pregnant women and their partners should take measures to prevent Zika virus infection during pregnancy. A list of affected areas and specific recommendations on how to prevent Zika virus infection during pregnancy are available at https://www.cdc.gov/pregnancy/zika/protect-yourself.html., Competing Interests: No conflicts of interest were reported.
- Published
- 2018
- Full Text
- View/download PDF
32. Update: Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus Exposure - United States (Including U.S. Territories), July 2017.
- Author
-
Oduyebo T, Polen KD, Walke HT, Reagan-Steiner S, Lathrop E, Rabe IB, Kuhnert-Tallman WL, Martin SW, Walker AT, Gregory CJ, Ades EW, Carroll DS, Rivera M, Perez-Padilla J, Gould C, Nemhauser JB, Ben Beard C, Harcourt JL, Viens L, Johansson M, Ellington SR, Petersen E, Smith LA, Reichard J, Munoz-Jordan J, Beach MJ, Rose DA, Barzilay E, Noonan-Smith M, Jamieson DJ, Zaki SR, Petersen LR, Honein MA, and Meaney-Delman D
- Subjects
- Centers for Disease Control and Prevention, U.S., Female, Humans, Pregnancy, United States, Health Personnel, Practice Guidelines as Topic, Pregnancy Complications, Infectious prevention & control, Zika Virus Infection prevention & control
- Abstract
CDC has updated the interim guidance for U.S. health care providers caring for pregnant women with possible Zika virus exposure in response to 1) declining prevalence of Zika virus disease in the World Health Organization's Region of the Americas (Americas) and 2) emerging evidence indicating prolonged detection of Zika virus immunoglobulin M (IgM) antibodies. Zika virus cases were first reported in the Americas during 2015-2016; however, the incidence of Zika virus disease has since declined. As the prevalence of Zika virus disease declines, the likelihood of false-positive test results increases. In addition, emerging epidemiologic and laboratory data indicate that, as is the case with other flaviviruses, Zika virus IgM antibodies can persist beyond 12 weeks after infection. Therefore, IgM test results cannot always reliably distinguish between an infection that occurred during the current pregnancy and one that occurred before the current pregnancy, particularly for women with possible Zika virus exposure before the current pregnancy. These limitations should be considered when counseling pregnant women about the risks and benefits of testing for Zika virus infection during pregnancy. This updated guidance emphasizes a shared decision-making model for testing and screening pregnant women, one in which patients and providers work together to make decisions about testing and care plans based on patient preferences and values, clinical judgment, and a balanced assessment of risks and expected outcomes.
- Published
- 2017
- Full Text
- View/download PDF
33. Update: Interim Guidance for Preconception Counseling and Prevention of Sexual Transmission of Zika Virus for Persons with Possible Zika Virus Exposure - United States, September 2016.
- Author
-
Petersen EE, Meaney-Delman D, Neblett-Fanfair R, Havers F, Oduyebo T, Hills SL, Rabe IB, Lambert A, Abercrombie J, Martin SW, Gould CV, Oussayef N, Polen KN, Kuehnert MJ, Pillai SK, Petersen LR, Honein MA, Jamieson DJ, and Brooks JT
- Subjects
- Centers for Disease Control and Prevention, U.S., Condoms statistics & numerical data, Female, Humans, Male, Mass Screening, Pregnancy, Residence Characteristics statistics & numerical data, Sexual Abstinence, Travel statistics & numerical data, United States, Zika Virus Infection transmission, Counseling, Guidelines as Topic, Pregnancy Complications, Infectious prevention & control, Sexually Transmitted Diseases, Viral prevention & control, Zika Virus Infection prevention & control
- Abstract
CDC has updated its interim guidance for persons with possible Zika virus exposure who are planning to conceive (1) and interim guidance to prevent transmission of Zika virus through sexual contact (2), now combined into a single document. Guidance for care for pregnant women with possible Zika virus exposure was previously published (3). Possible Zika virus exposure is defined as travel to or residence in an area of active Zika virus transmission (http://www.cdc.gov/zika/geo/index.html), or sex* without a condom
† with a partner who traveled to or lived in an area of active transmission. Based on new though limited data, CDC now recommends that all men with possible Zika virus exposure who are considering attempting conception with their partner, regardless of symptom status,§ wait to conceive until at least 6 months after symptom onset (if symptomatic) or last possible Zika virus exposure (if asymptomatic). Recommendations for women planning to conceive remain unchanged: women with possible Zika virus exposure are recommended to wait to conceive until at least 8 weeks after symptom onset (if symptomatic) or last possible Zika virus exposure (if asymptomatic). Couples with possible Zika virus exposure, who are not pregnant and do not plan to become pregnant, who want to minimize their risk for sexual transmission of Zika virus should use a condom or abstain from sex for the same periods for men and women described above. Women of reproductive age who have had or anticipate future Zika virus exposure who do not want to become pregnant should use the most effective contraceptive method that can be used correctly and consistently. These recommendations will be further updated when additional data become available.- Published
- 2016
- Full Text
- View/download PDF
34. Zika Virus Disease Cases - 50 States and the District of Columbia, January 1-July 31, 2016.
- Author
-
Walker WL, Lindsey NP, Lehman JA, Krow-Lucal ER, Rabe IB, Hills SL, Martin SW, Fischer M, and Staples JE
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, District of Columbia epidemiology, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Pregnancy, Travel statistics & numerical data, United States epidemiology, Young Adult, Zika Virus Infection prevention & control, Zika Virus Infection transmission, Zika Virus isolation & purification, Zika Virus Infection epidemiology
- Abstract
Zika virus is a mosquito-borne flavivirus primarily transmitted to humans by Aedes aegypti mosquitoes (1). Zika virus infections have also been documented through intrauterine transmission resulting in congenital infection; intrapartum transmission from a viremic mother to her newborn; sexual transmission; blood transfusion; and laboratory exposure (1-5). Most Zika virus infections are asymptomatic (1,6). Clinical illness, when it occurs, is generally mild and characterized by acute onset of fever, maculopapular rash, arthralgia, or nonpurulent conjunctivitis. However, Zika virus infection during pregnancy can cause adverse outcomes such as fetal loss, and microcephaly and other serious brain anomalies (1-3). Guillain-Barré syndrome, a rare autoimmune condition affecting the peripheral nervous system, also has been associated with Zika virus infection (1). Following the identification of local transmission of Zika virus in Brazil in May 2015, the virus has continued to spread throughout the Region of the Americas, and travel-associated cases have increased (7). In 2016, Zika virus disease and congenital infections became nationally notifiable conditions in the United States (8). As of September 3, 2016, a total of 2,382 confirmed and probable cases of Zika virus disease with symptom onset during January 1-July 31, 2016, had been reported from 48 of 50 U.S. states and the District of Columbia. Most cases (2,354; 99%) were travel-associated, with either direct travel or an epidemiologic link to a traveler to a Zika virus-affected area. Twenty-eight (1%) cases were reported as locally acquired, including 26 associated with mosquito-borne transmission, one acquired in a laboratory, and one with an unknown mode of transmission. Zika virus disease should be considered in patients with compatible clinical signs or symptoms who traveled to or reside in areas with ongoing Zika virus transmission or who had unprotected sex with someone who traveled to those areas. Health care providers should continue to educate patients, especially pregnant women, about the importance of avoiding infection with Zika virus, and all pregnant women should be assessed for possible Zika virus exposure at each prenatal visit (2).
- Published
- 2016
- Full Text
- View/download PDF
35. Interim Guidance for Interpretation of Zika Virus Antibody Test Results.
- Author
-
Rabe IB, Staples JE, Villanueva J, Hummel KB, Johnson JA, Rose L, Hills S, Wasley A, Fischer M, and Powers AM
- Subjects
- Centers for Disease Control and Prevention, U.S., Dengue diagnosis, Dengue therapy, Female, Humans, Pregnancy, United States, Zika Virus Infection therapy, Antibodies, Viral isolation & purification, Diagnostic Tests, Routine, Practice Guidelines as Topic, Zika Virus immunology, Zika Virus Infection diagnosis
- Abstract
Zika virus is a single-stranded RNA virus in the genus Flavivirus and is closely related to dengue, West Nile, Japanese encephalitis, and yellow fever viruses (1,2). Among flaviviruses, Zika and dengue virus share similar symptoms of infection, transmission cycles, and geographic distribution. Diagnostic testing for Zika virus infection can be accomplished using both molecular and serologic methods. For persons with suspected Zika virus disease, a positive real-time reverse transcription-polymerase chain reaction (rRT-PCR) result confirms Zika virus infection, but a negative rRT-PCR result does not exclude infection (3-7). In these cases, immunoglobulin (Ig) M and neutralizing antibody testing can identify additional recent Zika virus infections (6,7). However, Zika virus antibody test results can be difficult to interpret because of cross-reactivity with other flaviviruses, which can preclude identification of the specific infecting virus, especially when the person previously was infected with or vaccinated against a related flavivirus (8). This is important because the results of Zika and dengue virus testing will guide clinical management. Pregnant women with laboratory evidence of Zika virus infection should be evaluated and managed for possible adverse pregnancy outcomes and be reported to the U.S. Zika Pregnancy Registry or the Puerto Rico Zika Active Pregnancy Surveillance System for clinical follow-up (9,10). All patients with clinically suspected dengue should have proper management to reduce the risk for hemorrhage and shock (11). If serologic testing indicates recent flavivirus infection that could be caused by either Zika or dengue virus, patients should be clinically managed for both infections because they might have been infected with either virus.
- Published
- 2016
- Full Text
- View/download PDF
36. Zika Virus Infection Among U.S. Pregnant Travelers - August 2015-February 2016.
- Author
-
Meaney-Delman D, Hills SL, Williams C, Galang RR, Iyengar P, Hennenfent AK, Rabe IB, Panella A, Oduyebo T, Honein MA, Zaki S, Lindsey N, Lehman JA, Kwit N, Bertolli J, Ellington S, Igbinosa I, Minta AA, Petersen EE, Mead P, Rasmussen SA, and Jamieson DJ
- Subjects
- Adult, Centers for Disease Control and Prevention, U.S., Female, Guidelines as Topic, Humans, Pregnancy, United States, Zika Virus Infection epidemiology, Pregnancy Complications, Infectious diagnosis, Travel, Zika Virus isolation & purification, Zika Virus Infection diagnosis
- Abstract
After reports of microcephaly and other adverse pregnancy outcomes in infants of mothers infected with Zika virus during pregnancy, CDC issued a travel alert on January 15, 2016, advising pregnant women to consider postponing travel to areas with active transmission of Zika virus. On January 19, CDC released interim guidelines for U.S. health care providers caring for pregnant women with travel to an affected area, and an update was released on February 5. As of February 17, CDC had received reports of nine pregnant travelers with laboratory-confirmed Zika virus disease; 10 additional reports of Zika virus disease among pregnant women are currently under investigation. No Zika virus-related hospitalizations or deaths among pregnant women were reported. Pregnancy outcomes among the nine confirmed cases included two early pregnancy losses, two elective terminations, and three live births (two apparently healthy infants and one infant with severe microcephaly); two pregnancies (approximately 18 weeks' and 34 weeks' gestation) are continuing without known complications. Confirmed cases of Zika virus infection were reported among women who had traveled to one or more of the following nine areas with ongoing local transmission of Zika virus: American Samoa, Brazil, El Salvador, Guatemala, Haiti, Honduras, Mexico, Puerto Rico, and Samoa. This report summarizes findings from the nine women with confirmed Zika virus infection during pregnancy, including case reports for four women with various clinical outcomes. U.S. health care providers caring for pregnant women with possible Zika virus exposure during pregnancy should follow CDC guidelines for patient evaluation and management. Zika virus disease is a nationally notifiable condition. CDC has developed a voluntary registry to collect information about U.S. pregnant women with confirmed Zika virus infection and their infants. Information about the registry is in preparation and will be available on the CDC website.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.